Blog

  • Medoc will exhibit at NeuPSIG 2019

    21 April 2019
    150 Views

    Medoc Ltd. will exhibit at The 7th International Congress on Neuropathic Pain (NeuPSIG 2019), the international forum that provides the latest research and developments in understanding the mechanisms, assessment, prevention and treatment of neuropathic pain.

    The conference will be held this year on May 8-11 in London, and will focus on Diabetic Neuropathic Pain and Chemotherapy-induced Peripheral Neuropathic Pain.

    Join our MINI Symposium:

    “The use of Quantitative Sensory Testing in pharma-sponsored analgesic clinical trials: insights from recent trials” by Roi Treister. May 10th 12:45 at the Buckingham Room

    Attend the QST Workshop with Medoc devices:

    Hands-On workshop with leaders in the pain study field. May 10th 15:30-18:30 at the Windsor Suite

     

    You’re welcome to visit us at our Booth #202

    For the NeuPSIG scientific program

     

    Continue Reading
  • Thermal quantitative sensory testing proves pre-clinically relevant in type 2 Diabetes

    14 March 2019
    244 Views

    Thermal Quantitative Sensory testing (QST) is routinely performed in various diabetes clinics around the world to monitor for small fiber abnormalities.

    (more…)

    Continue Reading
  • Could Quantitative Sensory Testing help protect cancer patients from neuropathy?

    7 February 2019
    285 Views
    Comments are off for this post

    QST testing may detect subclinical neuropathy and hence, treatment may be adjusted in time.

    (more…)

    Continue Reading
  • QST identifies the better surgical skin graft technique

    24 January 2019
    306 Views
    Comments are off for this post

    QST identifies the better surgical skin graft technique:

    In a recent article published in the International Journal of Surgery, authors reported the use of a wide array of QST (quantitative sensory testing) techniques to identify which of three surgical flap techniques is the least damaging to sensory nerve function of the donor site.

    In this trial, which used Medoc’s TSA II and AlgoMed QST systems, thirty-one patients were included, by approximation equally divided among three types of surgical techniques. (more…)

    Continue Reading
  • Something to be optimistic about for 2019!

    2 January 2019
    404 Views
    Comments are off for this post
    Computerized Pressure Algometer

    What do the AlgoMed device, conditioned pain modulation and optimism have in common?

    (more…)

    Continue Reading
  • New technology may change the diagnosis and management of diabetic neuropathy

    15 November 2018
    406 Views
    Comments are off for this post
    World Diabetes Day

    Diabetic neuropathy is one of the most common complications seen in patients suffering from diabetes worldwide, with rates of neuropathies seen in up to 50% of diabetic patients (Gordois et al., 2003a; Gordois et al., 2003b). Medoc has been developing different tools which, with the use of thermal and vibratory stimuli, are able to evaluate the type and level of impairment in different nerve fibers. (more…)

    Continue Reading
  • AlgoMed – High Level Technology for Pain Diagnosis

    31 October 2018
    758 Views
    Comments are off for this post

    Algometry has been used in the past decade for the detection of pressure pain threshold in different body sites, including bones, muscles and tendons. Patients with fibromyalgia, for instance, have been tested in clinical trials, attempting to quantify and characterize their pain through algometry. However, measurement tools adopted to test pain in fibromyalgia studies, for example, were based on the clinician’s impression of the patient’s state, thus not giving a precise measure (Cheatham et al., 2018).

    (more…)

    Continue Reading
  • Publication spotlight

    4 September 2018
    613 Views
    Comments are off for this post

    A recent collaborative study by J. Schliessbach and colleagues [1], from Switzerland, Canada, Denmark and the US aimed to investigate if thermal QST can predict analgesic effects of oxycodone, imipramine and clobazam in chronic low back pain.

    Continue Reading
  • Growing QST Presence in Pharma Clinical Trials

    4 September 2018
    466 Views
    Comments are off for this post

    The use of QST devices in pharma sponsored clinical trials has been constantly rising during the last couple of years.
    This welcomed surge in QST incorporation in clinical trials comes as no surprise, following the growing understanding in both the research and pharma communities about the benefits of QST in promoting the success rates, safely and label-extension in analgesic pharma clinical trials.

    Continue Reading
  • APS & NZPS

    8 April 2018
    725 Views
    Comments are off for this post

    2018 Australian Pain Society 38th and New Zealand Pain Society Conjoint Annual Scientific Meeting

    Continue Reading